Forty enrolled participants and a readout expected before year-end: that is the entirety of Denali’s evidence base for DNL593 in GRN-related frontotemporal dementia, and it now rests entirely on Denali’s shoulders after Takeda walked away from the co-development agreement in April. Takeda’s exit, attributed to internal strategy rather than any safety or efficacy signal, reframes what was a shared risk into a solo bet — one Denali is carrying without a commercial partner at precisely the moment the Phase 1/2 data will either validate or undermine progranulin replacement as a therapeutic concept in FTD.
The clinical logic here is credible. DNL593 uses Denali’s Protein TransportVehicle to shuttle progranulin across the blood-brain barrier intravenously, addressing the root enzymatic deficit in a genetically defined patient population. With full enrollment at 40 participants, the study is no longer a recruitment question — it is a signal question. FTD-GRN is uniformly fatal, genetically homogeneous, and has no approved disease-modifying treatment, which means the bar for a meaningful biological effect is real but the regulatory path under accelerated approval is navigable if biomarker data hold up. The AVLAYAH approval — granted March 25 for Hunter syndrome and the first therapy to exploit transferrin receptor-mediated BBB crossing — gives Denali a live proof-of-concept for the TransportVehicle platform that directly strengthens the mechanistic argument for DNL593.
Simultaneously, the first patient dosed in the Phase 1b study of DNL628 — an oligonucleotide targeting the MAPT gene to reduce tau in Alzheimer’s disease — opens a second high-stakes CNS program. The OTV platform is less clinically validated than the ETV or PTV variants, and tau reduction via peripheral IV delivery of an antisense-like construct is an ambitious pharmacological ask. Data are not expected until first-half 2027, so DNL628 is a slow burn. The LRRK2 inhibitor BIIB122, partnered with Biogen, reads out from the Phase 2b LUMA study in mid-2026 and represents the nearest inflection point across the entire neurodegenerative portfolio.
The DNL593 end-of-2026 readout is the most consequential near-term clinical event to track: if progranulin restoration produces a durable CSF or cognitive signal in a fully enrolled, genetically confirmed FTD population, Denali moves from rare-disease commercial story to legitimate CNS platform company — without a partner to share either the credit or the cost.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
